Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
NEAT 001/ANRS 143 Study Group, Jan Gerstoft (Member of author group)
26Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART'. Together they form a unique fingerprint.
Keyphrases
Nursing and Health Professions
Pharmacology, Toxicology and Pharmaceutical Science